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All viral  tumors investigated have been found to contain specific antigens 
common for all the neoplasms induced by the same virus but usually different 
for tumors induced by different viruses (1, 2). This pattern was demonstrated 
first for transplantation  antigens,  and has subsequently been demonstrated for 
the so called neoantigens detected by the complement fixation  (CF) technique 
(3-5).  These  latter  antigens  are  probably identical  with  those  detected  by 
fluorescent  antibody  (FA)  tests  on fixed  cell  preparations  (6).  The  specific 
surface antigens detected by the FA technique in living leukemia cells are prob- 
ably identical with the transplantation antigens of these cells (7). 
The human adenovirus type 12 induces tumors in hamsters,  rats,  and mice 
(8,  9).  The  hamster  neoplasms  have  been  extensively  studied  for  their 
content  of virion  antigens  and  neoantigens.  Infectious virus  has  never  been 
recovered from tumors induced by adeno 12 virus (8, 10, 11), although indirect 
indications have been obtained for the presence  of the type-specific  C virion 
antigen  in hamster  tumors  (12,  13),  by use of the  CF and immunodiffusion 
techniques.  Sera of hamsters carrying primary tumors were found to  contain 
antibodies against the C antigen although this antigen was never detected when 
tumor cell preparations  were tested directly.  Indications for the existence of 
another virion  antigen (called antigen D) in hamster tumor cells has been ob- 
tained by immunodiffusion  tests (13). 
Extracts of hamster adeno 12 tumors have been found to contain a common 
specific antigen  (the so called neoantigen)  detectable by the CF and immuno- 
diffusion techniques (10, 13). This antigen appears to be identical with an anti- 
gen synthesized early during the in vitro infection cycle of human  cells (14). 
In addition the neoantigen as detected by FA technique has been reported to 
appear in other mammalian  cells  (monkey, hamster,  mouse, rabbit,  rat,  and 
chick) infected in vitro (15). In CF tests the adeno 12 neoantigen cross-reacts 
with a similar antigen present in neoplasms induced by adenovirus types 18 and 
31 and with the antigens produced in human cells infected by these viruses.  It 
* On leave  from Roswell  Park Memorial Institute, Buffalo,  N. ¥. 
689 690  TRANSPLANTATION  ANTIGENS  OF  ADENO  12  MOUSE  SARCOMAS 
does not cross-react with any of the corresponding antigens produced during the 
lyric infection cycle of other adenovirus types; e.g. type 7 (16).  The adeno  7 
neoantigen on the other hand cross-reacts with the corresponding antigens in- 
duced by types 3, 4, 11, 14, 16, and 21. A somewhat different cross-reactivity has 
been reported by use of the fluorescent antibody test  (23).  Serum of hamsters 
bearing adeno 12 tumors reacted not only with adeno 12 and 18 tumor cells but 
also with hamster and human cells infected with adenovirus types 1 and 7. 
It has been found with neoplasms induced by polyoma virus, SV40 virus, and 
Rous sarcoma virus, that their common specific transplantation antigens can be 
demonstrated  as specific isograft immunity in mice treated  by (a)  any tumor 
cells of the same viral origin, and (b) infection with the corresponding virus (2). 
The mechanism for the induction of immunity by virus infection is probably 
the following: the virus infects some host cells and induces in them the synthesis 
of an  antigen  identical  with  the  tumor-specific  transplantation  antigen.  The 
host animal will react immunologically against this antigen and would therefore 
reject isografts having the antigen. 
Infection of mice with  adeno  12  virus  has  been shown to induce  a  specific 
isograft immunity against  adeno  12  tumors  (17).  The present  results  demon- 
strate  a  common specific antigenicity of the transplantation  type in adeno  12 
mouse sarcomas  and  suggest  a  cross-reaction between  adeno  12  and  adeno  7 
tumors. 
Materials and Methods 
Mice.--Mice of the inbred strains  C3ttf/KL, CBA, A/Sn, and A.CA and the F1 hybrids 
between these strains were used. Their breeding and maintenance have been described (18). 
Virm.--Adenovirus types 18, 12, 7, and 5 were kept by passage on the stable human cell 
line  MAS  (19). Types  18  (D.C.),  12  (Huie),  and  7  (Gomen) were  kindly  supplied 
by Dr. Kjell6n in Malm~i, who had obtained types 18 and 12 from the National Institutes of 
Health, Bethesda, Md., in 1962 and type 7 from Dr. Pereira. Adenovirus type 5 was supplied 
by Dr. E. Norrby in Stockholm. Virus preparations used for tumor induction and immuniza- 
tion were prepared by disrupting packed MAS cells infected with adenovirus when CPE (cyto- 
pathic effect) was completed, by free~g and thawing five times and subsequent Freon treat- 
ment. Plaque titration of the viruses was performed on MAS cells by use of standard techniques 
with an observation period of 21 days (19). Titers of virus type 12 varied between 2.6 )< 105 
and  7.3 X  l0  s PFU/0.1  ml,  for type 7 the range was 1.3 X  l0  s -- 2.1 X  l0  T PFU/0.1 ml. 
Adenovirus type 18 was not titrated.  The polyoma virus used was originally obtained from 
Dr. B. E. Eddy. For control immunization purposes 128 HA units of virus were inoculated per 
animal. 
Sera of mice which had been treated  repeatedly with adenoviruses and tested  for trans- 
plantation  immunity were titrated  with regard to antiviral antibodies (against type 7 and 12, 
respectively)  by use of gel-precipitation  technique  and  the hemagglutinin-inhibition  (HI) 
test. HI antibodies against adeno type 12 were demonstrated by the technique of Schmidt et 
al.  (20) using rat erythrocytes  in the presence of heterotypic  immune serum  (rabbit  anti- 
adeno 5). Mouse sera were adsorbed with kaolin and test red cells before the HI test against 
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Tumors. 
Adeno 12 tumors: Adenovirus type 12 in aliquots of 0.1 ml (containing 2.6 X  105 -- 7.3 X 
l0 s PFU) was inoculated subcutaneously into mice (less than 24 hr old) of the strains C3H/ 
KL, A/Sn, and the Fx hybrids between A/Sn and C3H, CBA, and C57BL. Tumors developed 
in 9 out of 47 animals surviving for more than 1 month (Table I). 8 neoplasms were obtained 
in the 22 C3H and (A X  C3H)  F1 mice inoculated (=36%) while no tumors developed in 
24 A/Sn and (A X  C57BL) F1 animals. The latency period varied between 58 and 270 days 
with an average of about 5 months. The tumors were of a  poorly differentiated sarcomatous 
type located in muscle or subcutaneous connective tissue at the site of inoculation. 
Four adeno  12  tumors were passaged  serially in syngeneic mice. They were designated 
A12.HA, A12.HC, A12.HD (all of C3H/KL origin), and A12.SBA (developed in a (A X  CBA) 
F1 mouse) (cf. Table I). These tumors required high ceil doses for growth upon transfer (more 
TABLE  I 
Induction  of Sarcomas  by Infection  of Newborn  Mice  (less than  24  hr  old) with Adenovirus 
Type 12 
Mouse strain 
F.3H 
A  X  C3H)F1 
A ×  CBA) Fx 
~./Sn 
A X  C57BL) F~ 
rotal. 
No. in- 
oculated 
18 
8 
3 
21 
8 
58 
No. surviving 
after 1 month 
14 
8 
1 
17 
7 
47 
No. of tumor 
positives  Latency periods 
days 
58,  125",  130,  165~,  180§ 
135,  195,  270 
15oll 
2-9 months 
* Tumor was designated A12.HD of male origin and was passaged serially in vivo. 
:~ Tumor was designated A12.HA of female origin and was passaged serially in vivo. 
§ Tumor was designated A12.HC of male origin and was passaged serially in vivo. 
1] Tumor was designated A12.SBA of female origin and was passaged serially in vivo. 
than 107 cells). As previously observed with polyoma and Rous tumors the threshold dose 
decreased during the first four to five passages, but was then stable during the subsequent five 
passages studied. Each of the tumors was dose titrated determining the threshold dose neces- 
sary for growth in all untreated recipients and in mice whole-body X-irradiated with 350 R 
24 hr previously. 
Control tumors: Three mouse sarcomas induced by the RSV-SR virus were used for control 
purposes. Two were induced in vivo: RSC of A/Sn origin and RCB of A.CA origin (21). The 
third tumor designated TCRBA was induced by RSV-SR infection of CBA mouse embryo 
cell cultures in vitro. All these cell lines have previously been found to contain transplantation 
antigen common for RSV-SR mouse sarcomas (21).  1 A  "spontaneous" mammary carcinoma 
designated SH2 developed in a C3H female carrying the MTV virus. 
Transplantation  tests: Crude suspensions of tumors were used for immunization purposes. 
The tumor tissue was pressed through a  60-mesh stainless steel screen into sterile basal salt 
solution (BSS), containing 100/~g streptomycin and 100 IU penicillin per ml to make a  10% 
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suspension. In tests for immunogenicity 0.1 ml doses of such suspensions  were inoculated sub- 
cutaneously in the flanks four to eight times with 1-3 wk intervals. Immunity tests were per- 
formed 1-2 wk after the last dose. When using tumors which were genetically compatible with 
the animals to be treated,  the cell suspensions  were X-irradiated with 8000 R  immediately 
TABLE II 
Results  of three Experiments  with  Tumor A12.SBA  Inoculated  into  Syngeneic  (A  X  CBA) 
Ft Hybrid Recipients Immunized with 4 Adeno 12-Induced  Tumors and Adenedruses 
5, 7, 12 or 18, Respectively 
Pretreatment* 
Untreated 
SH2-HR 
A12.SBA-HR 
A12.HA-HR 
A12.HC-HR 
A12.HD-HR 
MAS 
Ad.12 virus  -- 1/5 
Ad.18 virus 
Ad.  5 virus 
Polyoma virus  5  4/5 
Takes~ in syngeneic recipients 
Unirradiated 
Experiment 1 
__L06e __10~  TPD 50[l 
i/s13/l~  1.6  ×  lo  ~ 
~/sj2/5  i.3  x  ao~ 
)/50/5  >3.2  X  10  6 
t/5lO/5  2  x  lo  e 
>__2 X  105 
>2  X  105 
i 
,5  X  104 
Irradiated  (350R) § 
Experiment 2 
10ec______10~c  I04c  TPD 50 
5/5[4/4]0/5  3.2  X  104 
15/5]3/5J  8  X  104 
0/510/51  >__3.2  X  10  6 
0/5  >--3.2 X  10  e 
--0/5  >--3.2  X  105 
--0/4  ~>-3'2  X  106 
5/5[5/50/5  3.2  X  104 
Irradiated (350 R) 
Experiment 3 
10~c  10~c  TPD 50 
4/4  2/5  1.3  X  105 
5/5  2/5  1.3  X  l0  s 
I/5~  ~/5  >2×  10 6 
0/5  ~/5 _3.2  X  10  s 
2/5  2/5  5 X  105 
3/5  ~/5  8  X  106 
5/5  )/5  3.2x105 
1/5  )/5  >-2xlo  ~ 
3/5  1/5  5  X  105 
5/5  3/51  s  x  lo  4 
* Pretreatment was carried out with four to eight doses of crude tumor cell suspensions 
(irradiated with 8000 R) of a SH2 spontaneous mammary carcinoma, four different adeno 12 
mouse tumors  (including the test tumor)  and MAS human cells used for virus production. 
Treatment was also performed with three to four doses  of adeno 5,  7,  12 and  18 viruses and 
polyoma virus intraperitoneally and subcutaneously with the last  dose  1 wk prior to test. 
Figures denote the fraction of mice developing progressively growing tumors. 
§ X-Ray-irradiation performed 24 hr prior to the test isografting. 
[] TPD 50 =  the 50 per cent end points for tumor production calculated by the method 
of Kt~rber (22). 
¶ Two  other  recipients  developed  distinct  tumors  which  subsequently  regressed  (cf. 
Fig. 1). 
before inoculation. This is denoted by "HR" (heavily irradiated) after the designation of the 
tumor in Fig. 1 and the tables. This dose is known to "sterilize" a sufficient fraction of the cells 
to inhibit any tumor outgrowth even from very large numbers of cells. 
The pretreated groups of mice were challenged by subcutaneous inoculation of known num- 
bers of trypan blue-unstained cells obtained by trypsinizing tumor tissue harvested in vivo. 
In the majority of the experiments (as specified  in Results)  the recipients were whole-body 
irradiated with 350 R  24 hr prior to challenge isografting. This treatment has previously been 
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and would thus secure any demonstrated immunity as a true anamnestic response. This type 
of irradiation also decreases a subsequent secondary response although to a much lesser degree. 
Low levels of {mmunity might accordingly be missed when irradiated animals are used. Chal- 
lenges were performed with at least two different cell doses in each experiment and the 50% 
end points for tumor production (TPD 50) were calculated by the method of K~irber (22). 
RESULTS 
Isograft Immunity Induced by Adeno 12 Tumor Cells.--Three different mouse 
tumors induced by adeno 12 virus were isografted into mice pretreated with 
four to eight doses of X-ray-killed or genetically incompatible adeno 12 tumor 
TABLE  III 
Results  of  three Experiments  with  Tumor  Alg.HA  Inoculate~  into  Syngeneic  Recipients 
Immunized with Two Different  Adeno 12-1nduced  Tumors or Adeno-viruses  7 and 12 
Takes~ in genetically compatible recipients 
Irradiated  (350R)§  Irradiated (350R)  Unlrradiated 
Pretreatrnent*  Experiment I  Experiment 2  Experiment 3 
3X  3X  3X  TPD50[t 
Untreated 
SH2-HR 
A12.HA-HR 
A12.SBA-HR 
A12.SBA 
Ad. 12 virus 
Ad. 7 virus 
Polyoma virus 
10  6 ( 
4/4 
4/4 
2/4 
1/4 
tOSc 
~/4 
4/4 
c)/4 
1/4 
104c 
3/5 2.5  X  10  4 
_~ 10  5 
3  X  l0  s 
3  X  l0  s 
105 
3X  3X 
10*c  I05c 
s/s s/s 
4/4 4/4 
o/4 o/s 
i/~ o/s 
4/5 9/5 
4/4 3/s 
1/2 3/s 
s/s s/s 
3X[  TPD50  X  3X 
104(  !107c 106c 
1/5 5.3  X  104  4/4 3/10 
_< 1o  5  5/~ 
_> 10  7  4/4 
6.3  X  10  6 
1.6  X  lO  s  4/4 
2.5  X  l0  s  5/5 5/10 
8  X  105  5/5 3/10 
_< 105  3/8 
3 X  TPD 50  I06c 
0/5 2.5  X  106 
< 107 
< 107 
< 107 
3  X  106 
5  ×  106 
4  X  106 
*, :~, §, and ][ compare corresponding footnotes to Table II. 
cells in parallel with two kinds of controls: untreated mice or animals pretreated 
with a "spontaneous" mammary carcinoma. The recipients were usually whole- 
body irradiated with 350 R  to abolish nonspecific effects of the pretreatments. 
Tables II, III, and IV summarize the results. Recipients treated with adeno 12 
tumor material showed a very clear-cut transplantation immunity when com- 
pared to the simultaneously tested controls. The immunity was clearly demon- 
strated in  all  the combinations studied  and was  usually seen as  a  markedly 
reduced take frequency (TPD  50 usually being  10-100 times higher than in 
controls) but also as a prolonged latency period, decreased growth rate, and in 
one experiment with tumor A12.SBA as regression of initially growing tumors 
(c/. Fig. 1). The regressions occurred in one animal rapidly after the tumor had 
appeared and in another after the tumor had grown for about 5 wk with a maxi- 
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In order to exclude further any nonspecific immunogenicity of the adeno 12 
tumors the following experiments were performed: Mice immunized with adeno 
12  tumor  cells  were  challenged  with  genetically  compatible Rous  sarcomas. 
Serving as controls were mice treated with Rous sarcoma cells (expected to be 
immune),  animals treated with polyoma virus  or the spontaneous mammary 
carcinoma SH2 (expected to be nonimmune), and finally untreated recipients. 
The results are presented in Tables V and VI and show that pretreatment with 
the  adeno  12  tumors  A12.HA  and  A12.SBA  did  not  induce  any  immunity 
TABLE IV 
Results of Two Experiments with Tumor A 12.HD Inoculated into Syngeneic or Semisyngeneic 
F1 Hybrid Recipients Immunized with Three Different Adeno 12-Induced  Mouse 
Tumors or Adenoviruses 5, 7, and 12 
Pretreatment* 
Untreated 
SH2-HR 
A12.HD-HR 
A12.HA-HR 
A12.SBA-HR 
MAS cells 
Ad. 12 virus 
Ad. 7 virus 
Ad. 5 virus 
Polyoma virus 
Takes~ in genetically compatible, irradiated§ (350R) recipients 
_  106 
5/5 
3/3 
0/5 
3/5 
5/5 
Experiment 1  Experiment 2 
105  TPD 501t 
2/5  1.3  X  l0  s 
<3.2  X  105 
>3.2  X  106 
8  X  10  ~ 
<3.2  X  105 
10e 
5/5 
5/5 
1/5 
1/5 
5/5 
215¶ 
2/4 
5/5 
105  TPD 50 
4/4  <3.2  X  104 
5/5  <3.2  X  104 
0/5  2  X  106 
0/5  2  X  106 
5/5  <3.2  X  104 
1.3  X  106 
106 
<3.2  X  105 
*, ~, §, and [[ compare corresponding footnotes to Tables II and III. 
¶ Another recipient developed a distinct tumor which subsequently regressed (cf. Fig. 2). 
against  Rous  sarcomas. The simultaneously challenged mice pretreated  with 
Rous sarcoma cells did show an immunity as expected, thus proving that the 
experiments were performed in a way suitable for detection of graft immunity if 
there was any. 
Isografl Immunity induced by Adeno 12 and Adeno  7 Virus Infection.--It has 
been demonstrated with other viral tumors  (induced by polyoma, SV40,  and 
Rous virus) that infection of animals with an oncogenic virus causes a specifc 
immunity to isografts of tumors induced with this virus, but does not affect the 
growth  of similarly grafted  tumors  of other viral origin.  Trentin  et  al.  (17) 
reported  that  adenovirus  type  12  also  induces  this  type  of  specific isograft 
immunity. 
In  order  to  take  advantage  of  the  unusual  possibility  of  studying  the H.  O.  SJOGREN~ J.  MINOWADA, AND  J.  ANKERST  695 
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"10  - 
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4- 
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Number of days after inoculation 
FIO. 1.  Growth of 106 viable A12.SBA  tumor cells in syngeneic (A X  CBA) F1 hybrids, 
whole-body-irradiated 350R  24  hr previously. One group  (O .....  O)  was pretreated eight 
times with X-ray-killed SH2 cells (a spontaneous mammary carcinoma of C3H origin); another 
group (@  @) treated by seven inoculations of similarly killed A12.SBA  tumor cells; and 
a third group (ZX--.--A) pretreated  with four doses  of adeno 12 virus subcutaneously. Figures 
denote the take frequencies. Each curve represents the growth of one tumor. Note the regres- 
sion of two tumors in the group pretreated with A12SBA cells and  the very small  variation 
of tumor size within the group immunized with SH2 cells. (Compare Table n, Experiment 3). 
TABLE  V 
Result  of an  Experiment  with  Rous  Samoma  RSC  Inoculated  into  Whale-Body--Irradiated 
(350R) Semisyngeneic (A  X  CBA ) F1 Hybrid Recipients Immunized with Two 
Different Adeno 12-Induced  Tumors 
Pretreatment* 
Untreated 
SH2-HR 
RCB 
A12.HA-HR 
A12.SBA-HR 
Polyoma virus 
10  4  cells 
4/s 
4/4 
2/5 
5/5 
5/5 
5/5 
Takes~ after inoculation  of 
l0  t cells 
1/s 
0/5 
3/5 
3/5 
2/5 
TPD 50§ 
3.2  X  10  s 
_<3.2  X  10  s 
1.3  X  104 
8X  10  s 
8X  102 
1.3  X  10  s 
* Pretreatment was performed with crude irradiated suspensions of a spontaneous mam- 
mary carcinoma SH2  and with two adeno 12  mouse sarcomas, A12.HA and A12.SBA.  As 
positive control mice pretreated with the Rous sarcoma RCB were included. 
Compare corresponding footnote in previous tables. 
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TABLE  VI 
Result of an Experiment  with  Rous Sarcoma RCB Inoculated  into Whole-Body-Irradiated 
(350R) Semisyngeneic (ACA  X  CBA) F1 Hybrid Recipients Immunized with the 
Adeno 12 Virus-Induced A12.HA  Tumor 
Pretreatment* 
Untreated 
TCRBA-HR 
A12.HA-HR 
10  s cells 
5/5 
0/5 
5/5 
Takes:~ after inoculation of 
10  2 cells 
5/5 
1/5 
5/5 
TPD 50§ 
<3.2  X  10 
2  X  10  3 
-<3.2  ×  10 
* Pretreatment  performed with  irradiated  cells of the adeno  12  tumor A12.ItA and  the 
in vitro induced mouse Rous sarcoma TCRBA, respectively. 
~; Compare corresponding footnote, :~, Table II. 
§ Compare corresponding footnote,  l] Table II. 
TABLE  VII 
Summary of the lmmunogenicity and Immunosensitivity of the Neoplasms 
Tested in this Investigation 
A12.HA 
A12.HC 
A12.HD 
A12.SBA 
SH2 
RCB 
Ad. 12 virus 
Ad. 7 virus 
Ad. 5 virus 
MAS cells 
Polyoma virus 
Immunogenicity 
A12.HA  A12.HD 
+ 
+ 
+ 
+ 
Immunosensitivity 
A12.SBA 
+  + 
+ 
+  + 
+  + 
+  + 
+  + 
RSC 
+ 
RCB 
+, positive reaction; and -,  no reaction. 
specificity of this immunity that the more or less  closely related adenoviruses 
offer, experiments were carried out in which the effect of adenovirus 12 infection 
was compared with the effects of infection with adeno types 7 and 5  as well as 
control treatment with material from uninfected human cells prepared with the 
same technique as the virus materials.  The virus-treated animals were tested 
for isograft immunity in parallel with cell-pretreated mice in order to be able to 
compare  the  strength  of  immunities  induced.  The  results  are  presented  in H. O. SJOGREN, J.  MINOWADA,  AND  J.  ANKERST  697 
Tables II-IV and Figs.  1 and 2. It appears quite clear  that adenovirus 12 in- 
duces an isograff immunity against the adeno 12 tumors while adenovirus 5 and 
the control MAS cell preparation,  and the polyoma virus do not. Interesting 
enough,  infection with adenovirus  type 7 also  induced an immunity  against 
adeno 12 isografts.  This immunity was in some experiments as strong as  that 
induced by adeno 12 (Experiment 2, Table III, and Experiment 2, Table, IV) 
28-  :  :  Ad.5  imm 5/5 
o- --o  Ad. 7 imm. 2/4  /'°  /// 
o 
24-  a  .  -z~ Ad. 12 imm.3/5~2/5 
"['20-  ~' 
~ 12-  •  ."  "° 
0 
4- 
Ib  2'0  3'0  4'0  5'0  6'0 
Number of  days after  inoculation 
FIG. 2. Growth of 106 viable A12.HD tumor cells in semisyngeneic (A X  C3H) F1 hybrids, 
whole-body-irradiated  350R  24 hr  previously.  One group  (•  •)  was  pretreated  four 
times with adeno  5  virus subcutaneously;  another group  (O ..... O)  was treated  with four 
inoculations  of  adeno  7  virus;  and  the  third  group  (Z~  A) was  similarly  treated  with  adeno 
12 virus.  Figures  denote take  frequences.  The tumors in the first  group grew very similarly 
and  are  represented  by  an  average  curve.  In  the  other  groups  each  curve  represents  the  growth 
of  one  tumor.  Note the  regression  of  one  tumor  in  an  adeno 12 virus-treated  redpient  and  the 
very small  variation  of  growth  within  the  group treated  with adeno 5 virus. 
and in other experiments weaker (Experiment 3, Table II). It was demonstrable 
with all the three tumors used for isograft challenge  (A12.SBA,  A12.HA,  and 
AI2.HD). 
In order to exclude the possibility that the demonstrated immunity of adeno 
7 virus-infected mice against adeno 12 isografts was due to accidental contam- 
ination  with  adeno  12 virus, the serum of the resistant  mice were tested for 
antibody activity against adeno 12 virus.  For orientation, the gel-precipitatAon 
technique was first used. Antibodies against adeno type 7 virus were detected in 
sera from adeno 7-treated mice but none were found against adeno type 12. 
The same sera also contained HI antibodies against type 7 in a tater of 1:512. 
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12-infected mice, on the other hand, were found to contain high antibody titers 
against adeno 12. These results appear to rule out a contamination of the adeno 
7-treated animals with adeno type 12 virus. 
DISCUSSION 
The results demonstrate that mouse tumors induced by the human adeno- 
virus type 12 possess  common specific  transplantation antigen(s). These anti- 
gen(s) could be demonstrated as specific immunosensitivity of the tumor cells 
and as immunogenicity  as well (Table VII). 
The  relationship  between  the  demonstrated specific  transplantation  anti- 
gen(s) and the antigens previously detected by other techniques is unknown. 
Although the mouse tumor cells do not produce infectious virus it is quite possi- 
ble that virion antigens are present in association with the cell membrane in 
such a  way that they might be demonstrated as specific  transplantation anti- 
gens. The neoantigen as detected by the FA technique on fixed cells appears to 
be localized exclusively intracellularly (23),  which makes it unlikely that it is 
identical to  the  specific  transplantation antigen(s).  The  demonstration that 
adeno 7 virus infection induces an immunity to adeno 12 tumor isografts indi- 
cates that the transplantation antigens induced by adeno 12 and adeno 7 are at 
least partially cross-reacting. In contrast, the neoantigens of adeno 7 and adeno 
12 tumors do not cross-react (15). This difference in cross-reactivity is a further 
indication that the transplantation antigen(s) are not identical with the neo- 
antigens. The single experiment in which adeno 18-infected mice were included 
also indicated, although not conclusively, that tMs virus is capable of inducing 
an immunity. This is not surprising since adeno virus 18 is in many respects 
closely related to adeno 12 virus, expressed also as a partial cross-reaction be- 
tween their neoantigens. 
Also other questions are raised by the demonstration that the adeno virus 
types 7, 12, and 18 induce an isograft immunity against adeno 12 tumors while 
adeno 5 virus infection fails to do so. Might it be a general property of oncogmic 
types of adenovirus to induce transplantation antigens which at least cross- 
react partially with each other similarly to those induced by adeno 7 and 12 
viruses? The nononcogenic virus  types might,  as  adenovirus 5,  either be  in- 
capable of inducing specific transplantation antigens or might cause analogous 
antigens although of a distinct specificity. 
Similar to the neoantigens, the specific  transplantation antigens are main- 
tained in the course of serial passage of the tumor cells in vivo or in vitro. This 
makes it very likely that at least part of the virus genome is present in these 
cells and determines the continuous antigen synthesis. Direct proof for this has 
recently been obtained by DNA-RNA hybridization experiments both in the 
polyoma and the adeno 12  tumor systems. In both systems a  portion of the 
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complementary to the DNA of the virus in question (24, 25). Of interest in this 
connection is the finding of Green et al.2 that the RNA isolated from adeno 
tumor cells hybridizes not only with the DNA of the inducing virus type but to 
an appreciable extent also with the DNA of some other adenovirus types. In 
these  experiments  the  RNA  of  adeno  12  tumors  hybridized with adeno  18 
virus DNA but not with DNA of adeno type 7. 
The specific  immunity to adeno 12  tumors after treatment with adeno 12 
tumor cells, or after infection with adeno 12 or 7 viruses can also be demon- 
strated in vitro by the colony inhibition (CI) technique (26).  It was possible 
to  demonstrate  both  specific  humoral  antibody activity and  cellbound im- 
munity.  8 These results fully confirm the in vivo findings presented. The in vitro 
experiments also showed a cross-reaction between mouse and hamster tumors 
induced by adeno 12. The fact that the CI method discovered antibodies active 
against adeno 12 tumor cells in the adeno 7-infected mice indicates that it meas- 
ures the same antigen as the transplantation immunity tests and not the rico- 
antigen. This in vitro technique makes it possible to study further cross-reactiv- 
ity of the specific  transplantation antigens in tumors of different species  and 
might also allow a  closer investigation of the relationship between these anti- 
gens and the neoantigens and virion antigens. 
SUMM~Ry 
A specific isograft resistance against three different mouse adeno 12 sarcomas 
was demonstrated in mice treated with four to eight doses of viable or X-ray- 
killed adeno 12 mouse tumors. Whole-body X-ray irradiation with 350 R  24 hr 
previous to the test challenge did not abolish the resistance, indicating that it 
was due to a  true anamnestic immune reaction. This was further proven by 
the finding that similar treatment with tumors of other origin did not induce 
any immunity, nor did the treatment with adeno 12 tumor material induce any 
immunity against two neoplasms of Schmidt-Ruppin-Rous viral origin. 
The previous report by Trentin et al. (17) that adeno 12 infection leads to a 
specific transplantation immunity was fully confirmed. When the specificity of 
this virus-induced immunity was studied it was discovered that besides  adeno 
virus type 12, type 7 and probably type 18 also gave the same type of resistance 
while adenovirus type 5 did not. A contamination of the adeno 7-infected mice 
with adeno type 12 was excluded by testing pooled sera from these animals for 
anti-adeno 12 CF or HI antibodies. 
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